These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
408 related items for PubMed ID: 35584444
21. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer. van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L. BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667 [Abstract] [Full Text] [Related]
22. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Stabile A, Pellegrino A, Mazzone E, Cannoletta D, de Angelis M, Barletta F, Scuderi S, Cucchiara V, Gandaglia G, Raggi D, Necchi A, Karakiewicz P, Montorsi F, Briganti A. Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770 [Abstract] [Full Text] [Related]
23. Comparing the Diagnostic Performance of Multiparametric Prostate MRI Versus 68Ga-PSMA PET-CT in the Evaluation Lymph Node Involvement and Extraprostatic Extension. Arslan A, Karaarslan E, Güner AL, Sağlıcan Y, Tuna MB, Kural AR. Acad Radiol; 2022 May; 29(5):698-704. PubMed ID: 32768351 [Abstract] [Full Text] [Related]
24. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer. Kopp D, Kopp J, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz PI, Salomon G, Wiggermann P, Hammerer P, Schiffmann J. Urol Int; 2022 May; 106(1):56-62. PubMed ID: 33965965 [Abstract] [Full Text] [Related]
25. Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study. Ucar T, Gunduz N, Demirci E, Culpan M, Gunel H, Kir G, Atis RG, Yildirim A. Prostate; 2022 Nov; 82(15):1462-1468. PubMed ID: 35915579 [Abstract] [Full Text] [Related]
26. Rational use of Ga-68 PSMA PET-CT according to nomograms and risk groups for the detection of lymph node metastasis in prostate cancer. Madendere S, Kılıç M, Köseoğlu E, Aykanat İC, Eden AB, Coşkun B, Tekkalan FB, Balbay MD. Urol Oncol; 2024 Feb; 42(2):29.e9-29.e15. PubMed ID: 38114351 [Abstract] [Full Text] [Related]
27. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference. Hermsen R, Wedick EBC, Vinken MJM, van Kalmthout LWM, Küsters-Vandevelde HVN, Wijers CHW, Somford DM, van Basten JA. Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3929-3937. PubMed ID: 35543733 [Abstract] [Full Text] [Related]
28. One-Stop-Shop Whole-Body 68Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer. Thalgott M, Düwel C, Rauscher I, Heck MM, Haller B, Gafita A, Gschwend JE, Schwaiger M, Maurer T, Eiber M. J Nucl Med; 2018 Dec; 59(12):1850-1856. PubMed ID: 29794224 [Abstract] [Full Text] [Related]
29. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management. Haxhimolla J, Kua B, Gilbourd D, Haxhimolla H. Semin Oncol Nurs; 2020 Aug; 36(4):151044. PubMed ID: 32723519 [Abstract] [Full Text] [Related]
30. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography? Kulkarni SC, Sundaram PS, Padma S. Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366 [Abstract] [Full Text] [Related]
31. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients. Zang S, Shao G, Cui C, Li TN, Huang Y, Yao X, Fan Q, Chen Z, Du J, Jia R, Sun H, Hua Z, Tang J, Wang F. Oncotarget; 2017 Feb 14; 8(7):12247-12258. PubMed ID: 28103574 [Abstract] [Full Text] [Related]
32. 68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy. Kopp J, Kopp D, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz P, Schoerner W, Hammerer P, Schiffmann J. World J Urol; 2020 Dec 14; 38(12):3085-3090. PubMed ID: 32103332 [Abstract] [Full Text] [Related]
33. The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer. Meijer D, Ettema RH, van Leeuwen PJ, van der Kwast TH, van der Poel HG, Donswijk ML, Oprea-Lager DE, Bekers EM, Vis AN. BJU Int; 2023 Mar 14; 131(3):330-338. PubMed ID: 36069585 [Abstract] [Full Text] [Related]
34. Diagnostic Accuracy of 64Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience. Cantiello F, Gangemi V, Cascini GL, Calabria F, Moschini M, Ferro M, Musi G, Butticè S, Salonia A, Briganti A, Damiano R. Urology; 2017 Aug 14; 106():139-145. PubMed ID: 28438628 [Abstract] [Full Text] [Related]
35. Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study. Çelen S, Gültekin A, Özlülerden Y, Mete A, Sağtaş E, Ufuk F, Yüksel D, Yağcı B, Zümrütbaş AE. Urol Int; 2020 Aug 14; 104(9-10):684-691. PubMed ID: 32750695 [Abstract] [Full Text] [Related]
36. Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI. Szigeti F, Schweighofer-Zwink G, Meissnitzer M, Hauser-Kronberger C, Hitzl W, Kunit T, Forstner R, Pirich C, Beheshti M. Mol Imaging Biol; 2022 Feb 14; 24(1):50-59. PubMed ID: 34519966 [Abstract] [Full Text] [Related]
37. 68Ga-PSMA ligand PET/CT integrating indocyanine green-guided salvage lymph node dissection for lymph node metastasis after radical prostatectomy. Li TC, Wang Y, Xiao CT, Li MZ, Liu XP, Huang WT, Li LY, Li K, Di JM, Wen XQ, Gao X. Asian J Androl; 2022 Feb 14; 24(1):97-101. PubMed ID: 34213490 [Abstract] [Full Text] [Related]
38. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer. Yilmaz B, Turkay R, Colakoglu Y, Baytekin HF, Ergul N, Sahin S, Tugcu V, Inci E, Tasci AI, Cermik TF. Prostate; 2019 Jun 14; 79(9):1007-1017. PubMed ID: 31012125 [Abstract] [Full Text] [Related]
39. Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer. Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H. J Transl Med; 2017 Nov 07; 15(1):230. PubMed ID: 29115970 [Abstract] [Full Text] [Related]
40. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy. Du X, Dong Y, Liu J, Su Y, Zhu Y, Pan J, Dong B, Chen R, Liu J, Tong Z, Pienta KJ, Rowe SP, Dong L, Xue W. Prostate; 2023 Aug 07; 83(11):1112-1120. PubMed ID: 37165552 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]